Index RUT
P/E -
EPS (ttm) -2.63
Insider Own 59.07%
Shs Outstand 43.12M
Perf Week -8.48%
Market Cap 316.72M
Forward P/E -
EPS next Y -4.00
Insider Trans 0.00%
Shs Float 17.66M
Perf Month 5.16%
Income -91.63M
PEG -
EPS next Q -0.76
Inst Own 37.39%
Short Float 16.61%
Perf Quarter -45.79%
Sales 0.00M
P/S -
EPS this Y 96.28%
Inst Trans -
Short Ratio 4.73
Perf Half Y -74.50%
Book/sh 7.73
P/B 0.95
EPS next Y -19.95%
ROA -
Short Interest 2.93M
Perf Year -
Cash/sh 8.02
P/C 0.91
EPS next 5Y -
ROE -
52W Range 6.30 - 35.06
Perf YTD -75.53%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -26.98%
52W High -79.06%
Beta -
Dividend TTM -
Quick Ratio 14.86
Sales past 5Y -37.90%
Gross Margin -
52W Low 16.51%
ATR (14) 0.70
Dividend Ex-Date -
Current Ratio 14.86
EPS Y/Y TTM -
Oper. Margin 0.00%
RSI (14) 44.01
Volatility 8.04% 8.56%
Employees 96
Debt/Eq 0.03
Sales Y/Y TTM -
Profit Margin -
Recom 1.40
Target Price 41.25
Option/Short Yes / Yes
LT Debt/Eq 0.02
EPS Q/Q -119.89%
Payout -
Rel Volume 0.23
Prev Close 7.58
Sales Surprise -
EPS Surprise 4.05%
Sales Q/Q -
Earnings Aug 12 AMC
Avg Volume 620.17K
Price 7.34
SMA20 -1.37%
SMA50 -9.83%
SMA200 -54.20%
Trades
Volume 143,706
Change -3.17%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-03-24 Initiated
H.C. Wainwright
Neutral
$8
Mar-04-24 Initiated
Wells Fargo
Overweight
$44
Mar-04-24 Initiated
Morgan Stanley
Overweight
$40
Mar-04-24 Initiated
Leerink Partners
Outperform
$48
Mar-04-24 Initiated
JP Morgan
Overweight
$39
Aug-21-24 04:05PM
(PR Newswire) +13.36%
-5.36%
Aug-12-24 04:08PM
04:05PM
Jul-16-24 11:33AM
(Pharmaceutical Technology) +11.71%
08:52AM
04:05PM
Loading…
Jul-15-24 04:05PM
Jun-20-24 08:55AM
Jun-17-24 04:05PM
(PR Newswire) -17.21%
-5.70%
Jun-10-24 04:05PM
Jun-07-24 08:55AM
May-14-24 10:54PM
04:05PM
Apr-11-24 05:01PM
Mar-29-24 02:59PM
Mar-26-24 04:05PM
07:00AM
Loading…
Mar-14-24 07:00AM
(The Wall Street Journal)
Mar-07-24 07:26PM
06:14PM
Feb-12-24 04:39PM
Feb-07-24 10:29PM
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Walker Karen Marie Chief Technology Officer Jun 06 '24 Option Exercise 4.42 9,636 42,591 9,636 Jun 10 06:56 PM Jones Ryan Alexander Chief Financial Officer May 28 '24 Option Exercise 0.73 18,016 13,152 43,950 May 29 04:33 PM Vida Ventures, LLC 10% Owner Feb 12 '24 Buy 22.00 253,136 5,568,992 252,553 Feb 14 07:04 PM Bain Capital Life Sciences Inv 10% Owner Feb 12 '24 Buy 22.00 450,000 9,900,000 3,163,868 Feb 14 05:26 PM GILEAD SCIENCES, INC. 10% Owner Feb 12 '24 Buy 22.00 910,000 20,020,000 4,126,119 Feb 13 05:48 PM Northpond Ventures III GP, LLC Former 10% Owner Feb 12 '24 Buy 22.00 450,000 9,900,000 450,000 Feb 12 05:51 PM
Index RUT
P/E -
EPS (ttm) -1.22
Insider Own 20.56%
Shs Outstand 105.65M
Perf Week -3.04%
Market Cap 607.49M
Forward P/E -
EPS next Y -1.14
Insider Trans 0.02%
Shs Float 83.93M
Perf Month 6.68%
Income -115.16M
PEG -
EPS next Q -0.26
Inst Own 86.20%
Short Float 8.67%
Perf Quarter -2.38%
Sales 0.00M
P/S -
EPS this Y 44.78%
Inst Trans 8.99%
Short Ratio 4.30
Perf Half Y 17.11%
Book/sh 3.42
P/B 1.68
EPS next Y -16.58%
ROA -36.04%
Short Interest 7.27M
Perf Year 131.85%
Cash/sh 3.49
P/C 1.65
EPS next 5Y 38.60%
ROE -42.20%
52W Range 1.57 - 8.40
Perf YTD 26.65%
Dividend Est. -
P/FCF -
EPS past 5Y -29.69%
ROI -29.61%
52W High -31.55%
Beta 1.26
Dividend TTM -
Quick Ratio 21.81
Sales past 5Y 0.00%
Gross Margin -
52W Low 266.24%
ATR (14) 0.38
Dividend Ex-Date -
Current Ratio 21.81
EPS Y/Y TTM 38.27%
Oper. Margin 0.00%
RSI (14) 49.21
Volatility 6.72% 5.99%
Employees 71
Debt/Eq 0.08
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 15.50
Option/Short Yes / Yes
LT Debt/Eq 0.08
EPS Q/Q 51.36%
Payout -
Rel Volume 0.35
Prev Close 5.82
Sales Surprise -
EPS Surprise -0.22%
Sales Q/Q -
Earnings Aug 12 BMO
Avg Volume 1.69M
Price 5.75
SMA20 -0.93%
SMA50 1.58%
SMA200 15.38%
Trades
Volume 594,875
Change -1.20%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-01-24 Upgrade
JP Morgan
Neutral → Overweight
$11
Dec-21-23 Upgrade
BofA Securities
Neutral → Buy
$4 → $6
Oct-30-23 Initiated
Wells Fargo
Overweight
$11
May-26-23 Downgrade
BofA Securities
Buy → Neutral
$8 → $3
May-25-23 Downgrade
JP Morgan
Overweight → Neutral
$19 → $9
Sep-16-22 Initiated
Jefferies
Buy
$12
Sep-09-22 Initiated
BTIG Research
Buy
$15
Nov-30-21 Initiated
H.C. Wainwright
Buy
$40
Sep-23-21 Initiated
Cantor Fitzgerald
Overweight
$40
Jan-26-21 Initiated
Needham
Buy
$37
Aug-18-20 Initiated
JP Morgan
Overweight
$33
Aug-18-20 Initiated
Cowen
Outperform
Aug-18-20 Initiated
BofA Securities
Buy
$33
Show Previous Ratings
Sep-03-24 08:00AM
Aug-29-24 08:00AM
Aug-16-24 04:05PM
Aug-12-24 08:00AM
Aug-05-24 08:00AM
04:05PM
Loading…
Jul-16-24 04:05PM
Jul-11-24 06:09PM
(GlobeNewswire) +8.53%
+11.15%
Jun-29-24 08:48PM
Jun-28-24 09:40AM
Jun-27-24 09:55AM
Jun-25-24 05:00PM
05:00PM
Jun-24-24 06:35AM
Jun-18-24 08:00AM
Jun-17-24 04:05PM
09:40AM
Loading…
Jun-07-24 09:40AM
Jun-05-24 11:04PM
(GlobeNewswire) +13.36%
-13.25%
10:57AM
09:55AM
04:45AM
Jun-04-24 05:06PM
12:06PM
08:46AM
07:28AM
07:00AM
07:00AM
Jun-03-24 04:30PM
May-20-24 09:35AM
May-16-24 04:05PM
May-13-24 02:53PM
08:00AM
Loading…
08:00AM
May-09-24 08:00AM
May-07-24 12:30PM
May-01-24 10:15AM
08:00AM
Apr-25-24 09:35AM
Apr-17-24 09:40AM
Apr-16-24 04:05PM
09:00AM
Apr-14-24 12:52PM
Apr-10-24 06:15PM
Apr-03-24 08:00AM
Apr-01-24 12:00PM
09:55AM
Mar-28-24 05:31AM
Mar-26-24 08:53PM
04:05PM
Mar-18-24 04:05PM
Mar-14-24 08:40AM
Mar-12-24 02:51PM
Feb-27-24 08:00AM
Feb-21-24 08:00AM
Feb-20-24 04:05PM
Feb-13-24 01:10PM
Jan-18-24 09:40AM
Jan-17-24 11:06AM
Jan-07-24 08:00PM
Dec-27-23 06:30AM
Dec-20-23 05:27PM
05:10PM
05:08PM
Dec-18-23 04:01PM
Nov-22-23 04:01PM
Nov-14-23 07:20PM
Nov-13-23 06:30AM
Nov-09-23 06:30AM
Oct-24-23 06:30AM
Oct-18-23 04:01PM
Oct-10-23 06:30AM
Sep-19-23 06:30AM
Sep-18-23 04:01PM
Sep-08-23 09:35AM
Aug-07-23 06:30AM
Aug-02-23 04:01PM
Jul-30-23 12:00PM
Jul-27-23 06:30AM
Jul-24-23 06:30AM
Jun-14-23 08:36AM
May-30-23 10:40AM
May-26-23 03:05AM
May-25-23 11:52AM
10:12AM
May-24-23 04:01PM
May-16-23 04:01PM
May-08-23 04:01PM
Apr-11-23 06:30AM
Mar-25-23 08:04AM
Mar-06-23 06:30AM
Feb-27-23 06:30AM
Feb-16-23 04:05PM
Feb-12-23 07:35AM
Jan-17-23 04:30PM
Jan-08-23 09:00AM
Jan-06-23 06:30AM
Jan-04-23 06:30AM
Dec-01-22 09:55AM
Nov-21-22 06:13AM
Nov-17-22 04:01PM
Nov-15-22 09:55AM
Nov-03-22 06:30AM
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. It offers drugs that control or target huntington's and alzheimer's disease, multiple sclerosis, glaucoma, parkinson's disease, and spinal muscular atrophy. The company was founded by Ben Barres and Arnon Rosenthal on March 3, 2011 and is headquartered in Brisbane, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Yednock Ted EVP & CHIEF INNOVATION OFFICER Sep 05 '24 Sale 5.64 5,500 31,020 10,000 Sep 06 04:30 PM Yednock Ted Officer Sep 05 '24 Proposed Sale 5.64 5,500 31,020 Sep 05 10:15 AM Carson William H. Director Sep 03 '24 Buy 5.48 3,200 17,536 19,200 Sep 04 04:34 PM Yednock Ted EVP & CHIEF INNOVATION OFFICER Aug 29 '24 Sale 5.95 5,500 32,725 15,500 Aug 30 06:00 PM Yednock Ted Officer Aug 29 '24 Proposed Sale 5.95 5,500 32,725 Aug 29 02:08 PM Carson William H. Director Aug 01 '24 Buy 6.24 3,200 19,968 16,000 Aug 05 07:53 PM Overdorf Michael EVP & CHIEF BUSINESS OFFICER Jul 15 '24 Sale 6.02 784 4,720 94,622 Jul 17 04:49 PM Lew Jennifer EVP & CHIEF FINANCIAL OFFICER Jul 15 '24 Sale 6.03 1,104 6,657 86,468 Jul 17 04:48 PM Yednock Ted EVP & CHIEF INNOVATION OFFICER Jul 15 '24 Sale 6.02 1,106 6,658 71,365 Jul 17 04:46 PM Carson William H. Director Jul 01 '24 Buy 5.00 3,200 16,000 12,800 Jul 02 05:43 PM Carson William H. Director Jun 03 '24 Buy 4.83 3,200 15,459 9,600 Jun 05 04:23 PM Carson William H. Director May 01 '24 Buy 4.68 3,200 14,982 6,400 May 03 04:15 PM Carson William H. Director Apr 08 '24 Buy 6.07 3,200 19,411 3,200 Apr 10 07:17 PM Lew Jennifer EVP & CHIEF FINANCIAL OFFICER Feb 20 '24 Sale 5.53 2,593 14,339 82,058 Feb 21 04:31 PM Yednock Ted EVP & CHIEF INNOVATION OFFICER Feb 20 '24 Sale 5.51 2,604 14,348 72,471 Feb 21 04:31 PM Overdorf Michael EVP & CHIEF BUSINESS OFFICER Feb 20 '24 Sale 5.48 1,951 10,691 85,641 Feb 21 04:31 PM Overdorf Michael EVP & CHIEF BUSINESS OFFICER Feb 12 '24 Sale 5.53 1,349 7,460 48,592 Feb 14 07:59 PM Love Douglas PRESIDENT AND CEO Feb 12 '24 Sale 5.54 5,782 32,032 196,121 Feb 14 07:56 PM Lew Jennifer EVP & CHIEF FINANCIAL OFFICER Feb 12 '24 Sale 5.54 1,809 10,022 45,651 Feb 14 07:54 PM Yednock Ted EVP & CHIEF INNOVATION OFFICER Feb 12 '24 Sale 5.54 1,810 10,027 36,075 Feb 14 07:52 PM Yednock Ted EVP & Chief Innovation Officer Dec 27 '23 Option Exercise 1.63 21,000 34,176 21,000 Dec 29 04:12 PM Yednock Ted EVP & Chief Innovation Officer Dec 27 '23 Sale 4.52 21,000 94,966 0 Dec 29 04:12 PM Satter Muneer A Director Dec 26 '23 Buy 2.88 350,000 1,008,000 7,406,024 Dec 28 04:30 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite